## Joseph E Willis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8034690/publications.pdf

Version: 2024-02-01

51	3,461	26	50
papers	citations	h-index	g-index
52	52	52	6209
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Computerâ€extracted features of nuclear morphology in hematoxylin and eosin images distinguish <scp>s</scp> tage <scp>ll</scp> and <scp>lV</scp> colon tumors. Journal of Pathology, 2022, 257, 17-28.	4.5	4
2	Pilot Feasibility Study of Encapsulated Balloon in Assessing Response to Eosinophilic Esophagitis Therapy. Techniques and Innovations in Gastrointestinal Endoscopy, 2022, 24, 396-398.	0.9	O
3	Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-Grade Dysplasia. Clinical Cancer Research, 2022, 28, 3761-3769.	7.0	2
4	Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus. Gastroenterology, 2021, 160, 2043-2054.e2.	1.3	17
5	Artificial Intelligence in Surveillance of Barrett's Esophagus. Cancer Research, 2021, 81, 3446-3448.	0.9	2
6	Radiomic Texture and Shape Descriptors of the Rectal Environment on Post-Chemoradiation T2-Weighted MRI are Associated with Pathologic Tumor Stage Regression in Rectal Cancers: A Retrospective, Multi-Institution Study. Cancers, 2020, 12, 2027.	3.7	24
7	Radiomic Features of Primary Rectal Cancers on Baseline T <sub>2</sub> â€Weighted MRI Are Associated With Pathologic Complete Response to Neoadjuvant Chemoradiation: A Multisite Study. Journal of Magnetic Resonance Imaging, 2020, 52, 1531-1541.	3.4	50
8	Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor- $\hat{l}^2$ and JNK Signaling Pathways in Esophageal Cancer. Gastroenterology, 2019, 156, 1761-1774.	1.3	38
9	Evaluation of Patients with an Apparent False Positive Stool DNA Test: The Role of Repeat Stool DNA Testing. Digestive Diseases and Sciences, 2018, 63, 1449-1453.	2.3	21
10	Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. Science Translational Medicine, 2018, 10, .	12.4	127
11	Coregistration of Preoperative MRI with Ex Vivo Mesorectal Pathology Specimens to Spatially Map Post-treatment Changes in Rectal Cancer Onto In Vivo Imaging. Academic Radiology, 2018, 25, 833-841.	2.5	10
12	Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018, 33, 721-735.e8.	16.8	396
13	Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma. Journal of Clinical Pathology, 2018, 71, 1108-1115.	2.0	33
14	Clinical utility of reflex testing using focused next generation sequencing for management of patients with advanced lung adenocarcinoma Journal of Clinical Oncology, 2018, 36, e24199-e24199.	1.6	1
15	Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. Archives of Pathology and Laboratory Medicine, 2017, 141, 625-657.	2.5	75
16	Molecular Biomarkers for the Evaluation of Colorectal Cancer. Journal of Molecular Diagnostics, 2017, 19, 187-225.	2.8	108
17	Molecular Biomarkers for the Evaluation of Colorectal Cancer. American Journal of Clinical Pathology, 2017, 147, 221-260.	0.7	32
18	Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. Nature Communications, 2017, 8, 14400.	12.8	93

#	Article	IF	CITATIONS
19	Genomic regions associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study. PLoS ONE, 2017, 12, e0184962.	2.5	6
20	Identification of a key role of widespread epigenetic drift in Barrett's esophagus and esophageal adenocarcinoma. Clinical Epigenetics, 2017, 9, 113.	4.1	19
21	Association Between Germline Mutation in <i>VSIG10L</i> localogy, 2016, 2, 1333.	7.1	23
22	RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Research, 2016, 76, 5628-5633.	0.9	26
23	Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas. Molecular Genetics & Samp; Genomic Medicine, 2016, 4, 407-419.	1.2	4
24	Adverse Clinical Outcome Associated With Mutations That Typify African American Colorectal Cancers. Journal of the National Cancer Institute, 2016, 108, djw164.	6.3	7
25	Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nature Communications, 2016, 7, 11971.	12.8	203
26	Global DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use. Clinical Epigenetics, 2016, 8, 111.	4.1	26
27	Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 727-735.	2.5	10
28	Magnetic resonance enterography/enteroclysis in acquired small bowel diverticulitis and small bowel diverticulosis. European Radiology, 2016, 26, 2881-2891.	4.5	13
29	A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus. PLoS Computational Biology, 2016, 12, e1004919.	3.2	36
30	A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. PLoS ONE, 2016, 11, e0146435.	2.5	2
31	Methylated <i>B3GAT2</i> and <i>ZNF793</i> Are Potential Detection Biomarkers for Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1890-1897.	2.5	11
32	ENVE: a novel computational framework characterizes copy-number mutational landscapes in colorectal cancers from African American patients. Genome Medicine, 2015, 7, 69.	8.2	2
33	Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science, 2015, 348, aaa2340.	12.6	220
34	Novel recurrently mutated genes in African American colon cancers. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1149-1154.	7.1	118
35	Reply to Ashktorab et al.: Mutational landscape of colon cancers in African Americans. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2853-E2853.	7.1	1
36	Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs. Carcinogenesis, 2015, 36, 291-298.	2.8	12

#	Article	IF	CITATIONS
37	GNAS Mutations Identify a Set of Right-Sided, RAS Mutant, Villous Colon Cancers. PLoS ONE, 2014, 9, e87966.	2.5	39
38	Inactivating Mutation in the Prostaglandin Transporter Gene, <i>SLCO2A1</i> , Associated with Familial Digital Clubbing, Colon Neoplasia, and NSAID Resistance. Cancer Prevention Research, 2014, 7, 805-812.	1.5	29
39	Differences in DNA Methylation Signatures Reveal Multiple Pathways of Progression From Adenoma to Colorectal Cancer. Gastroenterology, 2014, 147, 418-429.e8.	1.3	170
40	Aberrant Vimentin Methylation Is Characteristic of Upper Gastrointestinal Pathologies. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 594-600.	2.5	41
41	A Segregation Analysis of Barrett's Esophagus and Associated Adenocarcinomas. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 666-674.	2.5	39
42	Assessment of Familiality, Obesity and Other Risk Factors for Early Age of Cancer Diagnosis in Adenocarcinomas of the Esophagus and Gastroesophageal Junction. American Journal of Gastroenterology, 2009, 104, 1913-1921.	0.4	44
43	Familiality in Barrett's Esophagus, Adenocarcinoma of the Esophagus, and Adenocarcinoma of the Gastroesophageal Junction. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1668-1673.	2.5	104
44	Detection in Fecal DNA of Colon Cancer–Specific Methylation of the Nonexpressed Vimentin Gene. Journal of the National Cancer Institute, 2005, 97, 1124-1132.	6.3	331
45	Identification of Barrett's Esophagus in Relatives by Endoscopic Screening. American Journal of Gastroenterology, 2004, 99, 2107-2114.	0.4	64
46	Biology versus terminology: East meets West in surgical pathology. Gastrointestinal Endoscopy, 2003, 57, 369-376.	1.0	21
47	Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointestinal Endoscopy, 2002, 55, 655-661.	1.0	92
48	Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nature Genetics, 2000, 26, 16-17.	21.4	420
49	E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Human Mutation, 1999, 14, 249-255.	2.5	247
50	p27 cell-cycle inhibitor is inversely correlated with lymph node metastases in right-sided colon cancer. Journal of Clinical Laboratory Analysis, 1999, 13, 291-295.	2.1	31
51	Polyomavirus Mimicking High Grade Transitional Cell Carcinoma. Journal of Urology, 1996, 156, 1764-1764.	0.4	17